Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy

Research output: Contribution to journalReview articlepeer-review


The programmed death 1 receptor (PD-1) and its ligand (PD-L1) are key molecules of immune checkpoint mechanisms in cancer and actually represent one of the main targets of immunotherapy. The predictive and prognostic values of PD-L1 expression alone in cancer patients is currently under debate due to the methodological assessment of PD-L1 expression and its temporal variations. Better detailed studies about the molecular basis of immunotherapy biomarkers are necessary. Here we summarize the current knowledge of PD-L1 gene modifications at genetic and epigenetic levels in different tumors, thus highlighting their reported correlation with cellular processes and potential impact on patient outcomes.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Publication statusPublished - Jan 1 2018


  • CD274/PD-L1
  • epigenetic modulation
  • genomic aberrations
  • polymorphisms

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy'. Together they form a unique fingerprint.

Cite this